Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures they have disclosed in the annual report on Form 20-F any US law and regulation changes in internal controls over financial reporting during the A number of provisions of US law and regulation apply to the period covered by the annual report on Form 20-F that have company because our shares are quoted on the New York Stock materially affected, or are reasonably likely to affect materially, Exchange NYSE in the form of ADSs.
the companys internal control over financial reporting, and they NYSE rules have disclosed, based on their most recent evaluation of internal In general, the NYSE rules permit the company to follow UK control over financial reporting, to the external auditors and the corporate governance practices instead of those applied in the ARC, all significant deficiencies and material weaknesses in the US, provided that we explain any significant variations.
This design or operation of internal controls over financial reporting explanation is contained in our Form 20-F, which can be accessed which are reasonably likely to affect adversely the companys from the Securities and Exchange Commissions SEC EDGAR ability to record, process, summarise and report financial database or via our website.
NYSE rules that came into effect in information, and any fraud regardless of materiality involving 2005 require us to le annual and interim written afrmations persons that have a significant role in the companys internal concerning the Audit & Risk Committee and our statement on control over financial reporting.
significant differences in corporate governance.
The Group has carried out an evaluation under the supervision Sarbanes-Oxley Act of 2002 and with the participation of its management, including the CEO Following a number of corporate and accounting scandals in and CFO, of the effectiveness of the design and operation the US, Congress passed the Sarbanes-Oxley Act of 2002. of the Groups disclosure controls and procedures as at Sarbanes-Oxley is a wide-ranging piece of legislation concerned 31 December 2015. largely with financial reporting and corporate governance.
There are inherent limitations to the effectiveness of any system As recommended by the SEC, the company has established of disclosure controls and procedures, including the possibility a Disclosure Committee.
The Committee reports to the CEO, of human error and the circumvention or overriding of the controls the CFO and to the Audit & Risk Committee.
It is chaired by the and procedures.
Accordingly, even effective disclosure controls Company Secretary and the members consist of senior managers and procedures can only provide reasonable assurance of from finance, legal, corporate communications and investor achieving their control objectives.
The CEO and CFO expect to complete these certications and report their conclusions on the effectiveness of disclosure controls External legal counsel, the external auditors and internal experts are and procedures in March 2016, following which the certicates invited to attend its meetings periodically.
It has responsibility for will be led with the SEC as part of our Groups Form 20-F. considering the materiality of information and, on a timely basis, determining the disclosure of that information.
It has responsibility Section 404: Managements annual report on internal control for the timely ling of reports with the SEC and the formal review over financial reporting of the Annual Report and Form 20-F.
In 2015, the Committee met In accordance with the requirements of section 404 of Sarbanes- 14 times.
Oxley, the following report is provided by management in respect of the companys internal control over financial reporting as Sarbanes-Oxley requires that the annual report on Form 20-F dened in Rules 13a-15 f and 15d-15 f under the US Securities contain a statement as to whether a member of our Audit & Risk Exchange Act of 1934 : Committee ARC is an audit committee financial expert as dened by Sarbanes-Oxley.
Such a statement for each of the relevant management is responsible for establishing and maintaining members of the ARC Stacey Cartwright and Judy Lewent is adequate internal control over financial reporting for the Group.
included in the Audit & Risk Committee report on page 89 and Internal control over financial reporting is designed to provide in their biographies on page 76.
Additional disclosure reasonable assurance regarding the reliability of financial requirements arise under section 302 and section 404 of reporting and the preparation of financial statements for external Sarbanes-Oxley in respect of disclosure controls and procedures purposes in accordance with IFRS and internal control over financial reporting.
management conducted an evaluation of the effectiveness of Section 302: Corporate responsibility for financial reports internal control over financial reporting based on the framework, Sarbanes-Oxley also introduced a requirement for the CEO and Internal Control Integrated Framework 2013 issued by the CFO to complete formal certications, conrming that: the Committee of Sponsoring Organisations of the Treadway they have each reviewed the annual report on Form 20-F Commission COSO based on their knowledge, the annual report on Form 20-F there have been no changes in the Groups internal control over contains no material misstatements or omissions financial reporting during 2015 that have materially affected, or are reasonably likely to affect materially, the Groups internal based on their knowledge, the financial statements and other control over financial reporting financial information fairly present, in all material respects, the financial condition, results of operations and cash ows as of management has assessed the effectiveness of internal control the dates, and for the periods, presented in the annual report over financial reporting as at 31 December 2015 and its on Form 20-F conclusion will be led as part of the Groups Form 20-F, and they are responsible for establishing and maintaining disclosure  LLP, which has audited the consolidated controls and procedures that ensure that material information is financial statements of the Group for the year ended 31 December made known to them, and have evaluated the effectiveness of 2015, has also assessed the effectiveness of the Groups internal these controls and procedures as at the year-end, the results of control over financial reporting under Auditing Standard No.
5 of such evaluation being contained in the annual report on Form 20-F the Public Company Accounting Oversight Board United States.
Their audit report will be led with the Groups Form 20-F. they are responsible for establishing and maintaining internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles 248 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Section 13 r of the US Securities Exchange Act Donations to political organisations and Section 13 r of the US Securities Exchange Act of 1934, as political expenditure amended, requires issuers to make specic disclosure in their With effect from 1 January 2009, to ensure a consistent approach annual reports of certain types of dealings with Iran, including to political contributions across the Group, we introduced a global transactions or dealings with government-owned entities, as well policy to stop voluntarily all corporate political contributions.
as dealings with entities sanctioned for activities related to terrorism or proliferation of weapons of mass destruction, even In the period from 1 January 2009 to 31 December 2015, the Group when those activities are not prohibited by US law and do not did not make any political donations to EU or non-EU organisations.
The Group does not have a legal entity based Notwithstanding the introduction of this policy, in accordance with in Iran, but it does export certain pharmaceutical and vaccine the Federal Election Campaign Act in the US, we continue to products to Iran, via sales by non-US entities, to two privately held support an employee-operated Political Action Committee PAC Iranian distributors.
The Group also does business, via non-US that facilitates voluntary political donations by eligible GSK entities, in other jurisdictions targeted by sanctions laws, including employees.
Syria, Crimea, North Korea and Sudan.
The PAC is not controlled by GSK.
Decisions on the amounts and We do not believe that any of the Groups direct dealings with recipients of contributions are made by participating employees Iran require specic disclosure under these requirements, and the exercising their legal right to pool their resources and make Group limits sales to Iran, North Korea, Syria, Sudan and Cuba to political contributions, which are subject to strict limitations.
essential medicines determined in part using criteria set by the In 2015, a total of US$446,727 2014 US$525,900 was World Health Organization.
The Group has no direct knowledge donated to political organisations by the GSK employee PAC.
of the identity of its distributors downstream customers in Iran, and it is possible that these customers include entities, such as At the AGM in May 2001, shareholders first authorised the government-owned hospitals and pharmacies, that are owned company to make donations to EU political organisations and to or controlled directly or indirectly by the Iranian government or incur EU political expenditure, under the provisions of the Political by persons or entities sanctioned in connection with terrorism Parties, Elections and Referendums Act 2000, of up to 100,000 or proliferation activities.
Because the Group has no direct each year.
This authority has since been renewed annually.
The knowledge of its distributors customers, it cannot establish the Companies Act 2006 requires companies to continue to obtain proportion of gross revenue or sales potentially attributable to shareholder approval before they can make donations to EU entities afliated with the Iranian government or parties sanctioned political organisations or incur EU political expenditure.
As a result, the Group is reporting the However, we do not make and do not intend to make donations to entire gross revenues nil and net losses 0.41 million political parties or independent election candidates, nor do we from the Groups sales to Iran in 2015. make any donations to EU political organisations or incur EU The Group is also aware that some hospitals or other medical political expenditure.
facilities in Lebanon may be afliated with or controlled by The denitions of political donations, political expenditure and Hezbollah, which is designated by the United States as a terrorist political organisations used in the legislation are very wide.
Again, the Group does not deal directly with such particular, the denition of EU political organisations may extend facilities and sells through distributors.
The Group is also unable to bodies such as those concerned with policy review, law reform, to identify with certainty the degree or nature of any afliation of the representation of the business community and special interest the end customers with Hezbollah, and the Group is unable to groups such as those concerned with the environment, which the establish the proportion of gross revenue or sales potentially company and its subsidiaries might wish to support.
As a result, attributable to reportable entities.
As a result, the Group is the denitions may cover legitimate business activities not in the reporting the entire gross revenues 37 million and net profits ordinary sense considered to be political donations or political 15 million from the Groups sales to Lebanon in 2015. expenditure.
Such activities are not designed to support any political party or independent election candidate.
The authority which the Board has sought annually is a precautionary measure to ensure that the company and its subsidiaries do not inadvertently breach the legislation.
GSK Annual Report 2015 249 Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below.
Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc.
All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated.
Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries 1506369 Alberta ULC Canada 100 Common 100 Action Potential Venture Capital Limited England & Wales 100 Ordinary 100 Adechsa GmbH Switzerland 100 Ordinary 100 Affymax Research Institute United States 100 Common 100 Alenfarma Especialidades Farmaceuticas, Limitada iv Portugal 100 Ordinary Quota 100 Allen & Hanburys Limited iv England & Wales 100 Ordinary 100 Allen & Hanburys Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 Allen Farmaceutica, S. A. Spain 100 Ordinary 100 Allen Pharmazeutika Gesellschaft m. b. H. Austria 100 Ordinary 100 Aners S. A iv Argentina 100 Non-endorsable Nominative Ordinary 100 Barrier Therapeutics, Inc. United States 100 Common 100 Beecham Group p l c England & Wales 100 20p Shares 'A': 5p Shares B 100 Beecham Pharmaceuticals Pte Limited Singapore 100 Ordinary 100 Beecham Pharmaceuticals S. A iv vi Ecuador 100 Nominative 100 Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Portugal 100 Ordinary Quota 100 Beecham S. A. iv Belgium 100 Ordinary 100 Biddle Sawyer Limited India 100 Equity 100 Biovesta Ilalari Ltd. Sti.
Turkey 100 Nominative 100 Burroughs Wellcome & Co Australia Pty Limited iv vi Australia 100 Ordinary 100 Burroughs Wellcome & Co Bangladesh Limited Bangladesh 100 Ordinary 100 Burroughs Wellcome International Limited England & Wales 100 Ordinary 100 Caribbean Chemical Company, Ltd. Cayman Islands 100 Ordinary 100 will be struck off on 31.03.16 Cascan GmbH & Co. KG Germany 100 Ordinary 100 Castleton Investment Ltd vi Mauritius 100 Ordinary 100 Cellzome GmbH Germany 100 Ordinary 100 Cellzome Limited England & Wales 100 Ordinary 100 Cellzome Therapeutics, Inc. iv United States 100 Ordinary 100 Cellzome, Inc. United States 100 Ordinary 100 Series A Preferred 100 Series B Preferred 100 Series C-1 Convertible Preferred 100 Series C-3 Convertible Preferred 100 Charles Midgley Limited iv England & Wales 100 Ordinary 100 Cumulative Preference 100 Clarges Pharmaceuticals Limited England & Wales 100 Ordinary 100 Preference 99.97 Colleen Corporation United States 100 Shares No Par Value Common 100 Corixa Corporation United States 100 Common 100 Coulter Pharmaceutical, Inc. iv United States 100 Common 100 Dealcyber Limited England & Wales 100 Ordinary 100 Desarrollo Energia Solar Alternativa S. L. Spain 100 Ordinary 100 Domantis Limited England & Wales 100 Ordinary 100 Duncan Flockhart Australia Pty Limited iv vi Australia 100 Ordinary 100 Duncan Pharmaceuticals Philippines Inc. Philippines 100 Common 100 Edinburgh Pharmaceutical Industries Limited Scotland 100 Ordinary: Preference 100 Eskaylab Limited England & Wales 100 10p Ordinary 100 Etex Farmaceutica Ltda Chile 100 Social Capital 100 Europharm Holding S. A. Romania 100 Nominative 100 Europharm S. A. Romania 100 Nominative 100 Fedialis Medica S. A. S. France 100 Ordinary 100 Fipar Thailand Ltd In liquidation Thailand 100 Ordinary 100 Genelabs Technologies, Inc. United States 100 Common 100 Glaxo AS iv Norway 100 Ordinary 100 Glaxo Group Limited England & Wales 100 Ordinary 100 Glaxo Kabushiki Kaisha iv Japan 100 Ordinary 100 250 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries continued Glaxo Laboratories Nigeria Limited iv Nigeria 100 Ordinary 100 Glaxo Laboratories Limited iv England & Wales 100 Ordinary 100 Glaxo Operations UK Limited England & Wales 100 Ordinary 100 Glaxo Properties BV Netherlands 100 Ordinary 100 Glaxo Verwaltungs GmbH vi Germany 100 Ordinary 100 Glaxo Wellcome Australia Pty Ltd iv vi Australia 100 Ordinary 100 Glaxo Wellcome Ceylon Limited Sri Lanka 100 Ordinary 100 Ordinary B 100 Glaxo Wellcome Farmaceutica, Limitada Portugal 100 Ordinary Quota 100 Glaxo Wellcome Holdings Limited In liquidation England & Wales 100 Ordinary 100 Glaxo Wellcome International B. V. v Netherlands 100 Ordinary 100 Glaxo Wellcome Manufacturing Pte Ltd Singapore 100 Ordinary 100 Glaxo Wellcome Production S. A. S. France 100 Ordinary 100 Glaxo Wellcome PST Pty Ltd iv vi Australia 100 Ordinary 100 Glaxo Wellcome UK Limited England & Wales 100 Ordinary 100 Glaxo Wellcome Vidhyasom Limited iv Thailand 100 Ordinary 100 Glaxo Wellcome, S. A. Spain 100 Ordinary 100 Glaxo, S. A. Spain 100 Ordinary 100 Glaxo-Allenburys Nigeria Limited iv Nigeria 100 Ordinary 100 Glaxochem UK Unlimited England & Wales 100 Ordinary 100 Ordinary B 100 Ordinary C 100 Glaxochem Pte Ltd v Singapore 100 Ordinary 100 GlaxoSmithKline Produtos Farmaceuticos, Limitada Portugal 100 Ordinary Quota 100 GlaxoSmithKline Cambodia Co. Ltd. Cambodia 100 Ordinary 100 GlaxoSmithKline China Investment Co Ltd China 100 Ordinary 100 GlaxoSmithKline China R&D Company Limited China 100 Equity 100 GlaxoSmithKline Cyprus Limited Cyprus 100 Ordinary 100 GlaxoSmithKline GSK S. R. L. Romania 100 Ordinary 100 GlaxoSmithKline Ireland Limited ii Ireland 100 Ordinary 100 GlaxoSmithKline Israel Ltd Israel 100 Ordinary 100 GlaxoSmithKline Malta Limited Malta 100 Ordinary 100 GlaxoSmithKline Private Limited iv Zimbabwe 100 Ordinary 100 GlaxoSmithKline Thailand Limited Thailand 100 Ordinary 100 GlaxoSmithKline A. E. B. E. Greece 100 Ordinary 100 GlaxoSmithKline AB Sweden 100 Ordinary 100 GlaxoSmithKline AG Switzerland 100 Ordinary 100 GlaxoSmithKline Algrie S. P. A. Algeria 100 Ordinary 100 GlaxoSmithKline Argentina S. A. Argentina 100 Ordinary 100 GlaxoSmithKline AS Norway 100 Ordinary 100 GlaxoSmithKline Asia Pvt.
Limited India 100 Equity 100 GlaxoSmithKline Australia Pty Ltd Australia 100 Ordinary 100 GlaxoSmithKline B. V. Netherlands 100 Ordinary 100 GlaxoSmithKline Beteiligungs GmbH Germany 100 Ordinary 100 GlaxoSmithKline Biologicals Shanghai Ltd. China 100 Ordinary 100 GlaxoSmithKline Biologicals Shenzhen Co. Ltd iv China 100 Ordinary 100 GlaxoSmithKline Biologicals Kft.
Hungary 100 Ordinary 100 GlaxoSmithKline Biologicals S. A. S. France 100 Ordinary 100 GlaxoSmithKline Biologicals SA Belgium 100 Ordinary: Preference 100 GlaxoSmithKline Brasil Limitada Brazil 100 Ordinary 100 GlaxoSmithKline Business Services S. A. iv vi Costa Rica 100 Ordinary 100 GlaxoSmithKline Capital Inc. United States 100 Ordinary 100 GlaxoSmithKline Capital plc England & Wales 100 Ordinary 100 GlaxoSmithKline Caribbean Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Chile Farmaceutica Limitada Chile 100 Social Capital 100 GlaxoSmithKline Colombia S. A. Colombia 100 Ordinary 100 GlaxoSmithKline Consumer Healthcare Investments Ireland 100 Ordinary 100 Ireland Limited ii v GlaxoSmithKline Consumer Healthcare Ireland IP Limited ii v Ireland 100 Ordinary 100 GlaxoSmithKline Consumer Healthcare Pakistan Limited Pakistan 100 Ordinary 100 GlaxoSmithKline Consumer Healthcare Sri Lanka England & Wales 100 Ordinary 100 Holdings Limited iv GlaxoSmithKline Consumer Holding B. V. Netherlands 100 Ordinary 100 GlaxoSmithKline d. o. o Bosnia and 100 Euro Quota 100 Herzegovina GSK Annual Report 2015 251 Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures continued Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries continued GlaxoSmithKline d. o. o. Croatia 100 Equity 100 GlaxoSmithKline doo Beograd Serbia 100 Ordinary 100 GlaxoSmithKline Ecuador S. A. Ecuador 100 Ordinary 100 GlaxoSmithKline Eesti OU Estonia 100 Ordinary 100 GlaxoSmithKline ehf Iceland 100 Ordinary 100 GlaxoSmithKline El Salvador S. A. fide C. V. El Salvador 100 Ordinary 100 GlaxoSmithKline EOOD Bulgaria 100 Ordinary 100 GlaxoSmithKline Export Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Export Panama S. A. Panama 100 Ordinary 100 GlaxoSmithKline Far East B. V. Netherlands 100 Ordinary 100 GlaxoSmithKline Finance plc England & Wales 100 Ordinary 100 GlaxoSmithKline GmbH & Co. KG Germany 100 Partnership Capital 100 GlaxoSmithKline Guatemala S. A. Guatemala 100 Ordinary 100 GlaxoSmithKline Holding AS Norway 100 Ordinary 100 GlaxoSmithKline Holdings Americas Inc. United States 100 Common 100 GlaxoSmithKline Holdings Ireland Limited England & Wales 100 Ordinary: Deferred 100 GlaxoSmithKline Holdings One Limited i England & Wales 100 Ordinary 100 GlaxoSmithKline Holdings Limited i England & Wales 100 Ordinary 100 GlaxoSmithKline Holdings Pty Ltd Australia 100 Ordinary 100 GlaxoSmithKline Honduras S. A. Honduras 100 Ordinary 100 GlaxoSmithKline IHC Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Ilaclari Sanayi five Ticaret A. S. Turkey 100 Nominative 100 GlaxoSmithKline Inc. Canada 100 Class A Common 100 Class C Preference 100 GlaxoSmithKline Insurance Ltd. Bermuda 100 Ordinary 100 GlaxoSmithKline Intellectual Property No.
2 Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Intellectual Property Development Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Intellectual Property Holdings Limited England & Wales 100 A Ordinary: B Ordinary 100 GlaxoSmithKline Intellectual Property Limited England & Wales 100 Ordinary: Deferred 100 GlaxoSmithKline Intellectual Property Management Limited England & Wales 100 Ordinary 100 GlaxoSmithKline International Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Investigacin y Desarrollo, S. L. Spain 100 Ordinary 100 GlaxoSmithKline Investment Holdings Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Investment Services Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Investments Ireland Limited ii v Ireland 100 Ordinary 100 GlaxoSmithKline Investments Pty Ltd Australia 100 Ordinary 100 GlaxoSmithKline K. K. Japan 100 Ordinary 100 GlaxoSmithKline Korea Limited South Korea 100 Ordinary 100 GlaxoSmithKline Latin America, S. A. Panama 100 Ordinary 100 GlaxoSmithKline Latvia SIA Latvia 100 Ordinary 100 GlaxoSmithKline Lietuva UAB Lithuania 100 Ordinary 100 GlaxoSmithKline Limited Hong Kong 100 Ordinary 100 GlaxoSmithKline LLC United States 100 LLC Interests 100 GlaxoSmithKline Manufacturing SpA Italy 100 Ordinary 100 GlaxoSmithKline Maroc S. A. Morocco 100 Ordinary 100 GlaxoSmithKline Medical and Healthcare Products Limited Hungary 100 Ordinary Quotas 100 GlaxoSmithKline Mercury Limited i England & Wales 100 Ordinary 100 GlaxoSmithKline Mexico S. A. fide C. V. Mexico 100 Ordinary A: Ordinary B 100 GlaxoSmithKline NZ Limited New Zealand 100 Ordinary 100 GlaxoSmithKline Oy Finland 100 Ordinary 100 GlaxoSmithKline Peru S. A. Peru 100 Ordinary 100 GlaxoSmithKline Pharma A S Denmark 100 Class A 100 GlaxoSmithKline Pharma GmbH Austria 100 Ordinary 100 GlaxoSmithKline Pharmaceutical Kenya Limited Kenya 100 Ordinary 100 GlaxoSmithKline Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 GlaxoSmithKline Pharmaceutical Sdn Bhd Malaysia 100 Ordinary 100 GlaxoSmithKline Pharmaceuticals Pvt Ltd iv Sri Lanka 100 Ordinary 100 GlaxoSmithKline Pharmaceuticals Suzhou Limited China 100 Ordinary 100 GlaxoSmithKline Pharmaceuticals Costa Rica S. A Costa Rica 100 Ordinary 100 GlaxoSmithKline Pharmaceuticals S. A. Poland 100 Ordinary A: Ordinary B: 100 Ordinary C: Ordinary D 100 252 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries continued GlaxoSmithKline Pharmaceuticals SA Belgium 100 Ordinary 100 GlaxoSmithKline Pharmaceuticals Ukraine LLC Ukraine 100 Chartered Capital 100 GlaxoSmithKline Philippines Inc Philippines 100 Common 100 GlaxoSmithKline Pte Ltd Singapore 100 Ordinary 100 GlaxoSmithKline Puerto Rico Inc. iv Puerto Rico 100 Common 100 GlaxoSmithKline Republica Dominicana S. A. Dominican Republic 100 Ordinary 100 GlaxoSmithKline Research & Development Limited England & Wales 100 Ordinary 100 GlaxoSmithKline S. A. Spain 100 Ordinary 100 GlaxoSmithKline S. p. A. Italy 100 Ordinary 100 GlaxoSmithKline s. r. o. Czech Republic 100 Ordinary 100 GlaxoSmithKline Services GmbH & Co. KG vi Germany 100 Partnership Capital 100 GlaxoSmithKline Services Inc. iv United States 100 Common 100 GlaxoSmithKline Services Unlimited i England & Wales 100 Ordinary 100 GlaxoSmithKline SL Holdings, LLC United States 100 LLC Interests 100 GlaxoSmithKline SL LLC United States 100 LLC Interests 100 GlaxoSmithKline SL LP iv England & Wales 100 Partnership 100 GlaxoSmithKline Slovakia s. r. o. Slovakia 100 Ordinary 100 GlaxoSmithKline South Africa Pty Limited South Africa 100 Ordinary 100 GlaxoSmithKline Superannuation Company Pty Ltd iv vi Australia 100 Ordinary 100 GlaxoSmithKline Trading Services Limited ii v Ireland 100 Ordinary 100 GlaxoSmithKline Trading ZAO Russia 100 Ordinary 100 GlaxoSmithKline Tunisia S. A. R. L. Tunisia 100 Ordinary 100 GlaxoSmithKline UK Limited England & Wales 100 Ordinary 100 GlaxoSmithKline Uruguay S. A. Uruguay 100 Registered Shares Provisory Stock 100 GlaxoSmithKline Venezuela C. A. Venezuela 100 Ordinary 100 GlaxoSmithKline Vietnam Limited Liability Company iv Vietnam 100 Equity Capital 100 Glycovaxyn AG iv vi Switzerland 100 Common: Preferred A, 100 Preferred B: Preferred C 100 Group Laboratories South Africa Pty Limited iv vi South Africa 100 Ordinary 100 Groupe GlaxoSmithKline S. A. S. France 100 Ordinary 100 GSK Business Service Centre Sdn Bhd Malaysia 100 Ordinary 100 GSK Commercial Sp.
z o. o. Poland 100 Ordinary 100 GSK d. o. o. Ljubljana Slovenia 100 Ordinary 100 GSK Employee Share Plan Pty Ltd Australia 100 Ordinary 100 GSK Kazakhstan LLP Kazakhstan 100 Partnership Interest 100 GSK Services Sp z o. o. Poland 100 Ordinary 100 GSK Vaccines GmbH Germany 100 Ordinary 100 GSK Vaccines Institute for Global Health S. r. l. Italy 100 Quota 100 GSK Vaccines S. r. l. Italy 100 Quota 100 GSK Vaccines Vertriebs GmbH Germany 100 Ordinary 100 Herbridge ii iv vi Ireland 100 Ordinary 100 HGS France S. a. r. l. France 100 Ordinary 100 HGS Luxembourg LLC iv vi United States 100 Common Interests 100 Horlicks Limited England & Wales 100 Ordinary 100 Human Genome Sciences Pacic Pty Ltd vi Australia 100 Ordinary 100 Human Genome Sciences, Inc. United States 100 Common 100 ID Biomedical Corporation of Quebec Canada 100 Common 100 ID Biomedical Corporation of Washington iv United States 100 Common 100 Instituto Luso Farmaco, Limitada iv Portugal 100 Ordinary Quota 100 InterPharma Dienstleistungen GmbH Austria 100 Quota 100 J&J Technologies, LC iv United States 100 Membership Interest 100 Laboratoire GlaxoSmithKline France 100 Ordinary 100 Laboratoire Pharmaceutique Algrien LPA Production SPA Algeria 100 Ordinary 100 Laboratoire Pharmaceutique Algrien SPA Algeria 100 Ordinary 100 Laboratoires Paucourt iv France 100 Ordinary 100 Laboratoires Saint-Germain iv France 100 Ordinary 100 Laboratorios Dermatologicos Darier, S. A fide C. V. Mexico 100 Ordinary A: Ordinary B 100 Laboratorios Farmaceuticos Stiefel Portugal LTDA iv Portugal 100 Ordinary Quota 100 Laboratorios Phoenix Sociedad Anonima Industrial Argentina 100 Non-endorsable Nominative Comercial Y Financiera Ordinary Shares 100 Laboratorios Stiefel fide Chile & CIA LTDA Chile 100 Social Capital 100 Laboratorios Stiefel fide Venezuela SA Venezuela 100 Ordinary 100 GSK Annual Report 2015 253 Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures continued Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries continued Laboratorios Stiefel Ltda.
Brazil 100 Ordinary 100 Laboratorios Wellcome fide Portugal Limitada iv Portugal 100 Ordinary Quota 100 Laboratorios Wellcome S. A.
In liquidation Uruguay 100 Ordinary 100 Maxinutrition Limited In liquidation England & Wales 100 Ordinary 100 Mixis Genetics Limited England & Wales 100 Ordinary 100 Ordinary Euro 100 Montrose Fine Chemical Company Ltd Scotland 100 Ordinary 100 Montrose Pharma Company Limited Hungary 100 Ordinary Quota 100 Montrose Pharma UAB iv Lithuania 100 Ordinary 100 Nanjing Meirui Pharma Co. Ltd China 100 Ordinary 100 Novartis Vaccines and Diagnostics AG vi Switzerland 100 Ordinary 100 Novartis Vaccines and Diagnostics Pty Ltd Australia 100 Ordinary 100 Novartis Vaccines and Diagnostics S. L. vi Spain 100 Ordinary 100 Okairos AG iv vi Switzerland 100 Common: Preferred A: 100 Preferred B 100 Penn Labs Inc. iv United States 100 Common 100 S. R. One International B. V. Netherlands 100 Ordinary 100 S. R. One, Limited United States 100 Units Common 100 Setrst Limited England & Wales 100 Ordinary 100 Smith Kline & French Laboratories Limited England & Wales 100 Ordinary 100 Smith Kline & French Portuguesa-Produtos Portugal 100 Ordinary Quota 100 Farmaceuticos, LDA iv SmithKline Beecham Australia Pty Ltd iv vi Australia 100 Ordinary 100 SmithKline Beecham Bangladesh Private Limited iv Bangladesh 100 Ordinary 100 SmithKline Beecham Cork Limited ii Ireland 100 Ordinary 100 SmithKline Beecham Export Limited England & Wales 100 Ordinary 100 SmithKline Beecham H Limited England & Wales 100 Non-Cumulative Non-Redeemable 100 Ordinary 100 SmithKline Beecham Investments Limited England & Wales 100 Ordinary 100 SmithKline Beecham Manufacturing Limited ii Ireland 100 Ordinary 100 SmithKline Beecham SWG Limited England & Wales 100 Ordinary 100 SmithKline Beecham Animal Health Company Canada 100 Common 100 SmithKline Beecham Biologicals US Partnership United States 100 Partnership Interests 100 SmithKline Beecham Egypt L. L. C. Egypt 100 Quotas 100 SmithKline Beecham Farma, S. A. Spain 100 Ordinary 100 SmithKline Beecham Holdings Australia Pty.
Limited iv vi Australia 100 Ordinary A: Ordinary B 100 SmithKline Beecham Inter-American Corporation iv United States 100 Shares No par Value Common 100 SmithKline Beecham Limited England & Wales 100 Ordinary 6.25p 100 SmithKline Beecham Marketing and Technical Services Limited England & Wales 100 Ordinary 100 SmithKline Beecham Nominees Limited England & Wales 100 Ordinary 100 SmithKline Beecham Overseas Limited England & Wales 100 Ordinary 100 SmithKline Beecham Pension Plan Trustee Limited iv England & Wales 100 Ordinary 100 SmithKline Beecham Pension Trustees Limited iv England & Wales 100 Ordinary 100 SmithKline Beecham Pharma GmbH & Co KG Germany 100 Partnership Capital 100 SmithKline Beecham Pharma Verwaltungs GmbH Germany 100 Ordinary 100 SmithKline Beecham Pharmaceuticals Pty Limited iv vi South Africa 100 Ordinary 100 SmithKline Beecham Pharmaceuticals Co. United States 100 Shares No par Value Common 100 SmithKline Beecham Port Louis Limited vi Mauritius 100 Ordinary 100 SmithKline Beecham Retirement Plan Nominees Australia 100 Ordinary 100 Pty Limited iv vi SmithKline Beecham Senior Executive Pension Plan England & Wales 100 Ordinary 100 Trustee Limited iv Stiefel Distributors Ireland Limited ii iv Ireland 100 Ordinary 100 Stiefel Dominicana SRL iv Dominican Republic 100 Ordinary Quotas 100 Stiefel Farma, S. A Spain 100 Ordinary 100 Stiefel GmbH & Co. KG Germany 100 Partnership Capital 100 Stiefel India Private Limited India 100 Equity 100 Stiefel Laboratories Ireland Limited ii Ireland 100 Ordinary 100 Stiefel Laboratories Maidenhead Ltd England & Wales 100 Ordinary 100 Stiefel Laboratories Thailand Ltd.
Liquidated 25 Jan 2016 Thailand 100 Ordinary: Preference 100 Stiefel Laboratories U. K. Ltd England & Wales 100 Ordinary 100 Stiefel Laboratories Limited iv England & Wales 100 Ordinary 100 254 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries continued Stiefel Laboratories Pte Limited Singapore 100 Ordinary 100 Stiefel Laboratories Pty Ltd iv vi Australia 100 Ordinary 100 Stiefel Laboratories SA Pty Ltd iv vi South Africa 100 Ordinary 100 Stiefel Laboratories Taiwan Ltd Liquidated 5 Jan 2016 Taiwan 100 Ordinary 100 Stiefel Laboratories, Inc. United States 100 Common 100 Stiefel Maroc SARL Morocco 100 Ordinary 100 Stiefel Polska SP Z O. O. w likwidacji In liquidation Poland 100 Ordinary 100 Stiefel Research Australia Holdings Pty Ltd iv Australia 100 Ordinary 100 Stiefel Research Australia Pty Ltd Australia 100 Ordinary 100 Stiefel Research Institute, Inc. vi United States 100 Common 100 Stiefel Sales, Inc. iv vi United States 100 Common 100 Stiefel West Coast LLC United States 100 LLC Interests 100 Strebor Inc. United States 100 USD 1 par value Common 100 Tempero Pharmaceuticals, Inc. United States 100 Series A Preference 100 Series B Preference: Common 100 The Sydney Ross Co. iv United States 100 Ordinary 100 The Wellcome Foundation Limited England & Wales 100 Ordinary 100 UCB Pharma Thailand Ltd Liquidated 25 Jan 2016 Thailand 100 Ordinary 100 UCB Pharma Asia Pacic Sdn Bhd iv Malaysia 100 Ordinary 100 Webderm, Inc. iv vi United States 100 Common 100 Wellcome Consumer Healthcare Limited iv England & Wales 100 Ordinary 100 Wellcome Consumer Products Limited iv England & Wales 100 Ordinary 100 Wellcome Developments Pty Ltd iv vi Australia 100 Ordinary 100 Wellcome Limited England & Wales 100 Ordinary 100 Wellcome Operations Pty Ltd iv vi Australia 100 Ordinary 100 Subsidiaries where the effective interest is less than 100% Amoun Pharmaceutical Industries Co. S. A. E. Egypt 99.5 New Monetary Shares 99.5 Beecham Enterprises Inc. iv United States 55.9 Common 100 Block Drug Company, Inc. United States 63.5 Common 100 British Pharma Group Limited England & Wales 50 Capital 50 Block Drug Corporation iv United States 63.5 Common No Par Value 100 fide Micln a. s. Slovakia 63.5 Ordinary 100 Duncan Consumer Healthcare Philippines Inc Philippines 63.5 Common 100 Ex-Lax, Inc. Puerto Rico 63.5 Common 100 Fondation Novartis Consumer Health Pour I'Avancement Switzerland 63.5 Capital 63.5 Des Sciences Medicales, Biologiques Et Pharmaceutiques Glaxo Saudi Arabia Limited Saudi Arabia 49 Ordinary 49 GlaxoSmithKline Tianjin Co. Ltd China 90 Ordinary 90 GlaxoSmithKline Bangladesh Limited Bangladesh 82 Ordinary 82 GlaxoSmithKline Brasil Produtos para Consumo e Saude Ltda Brazil 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare China Co. Ltd China 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Hong Kong Limited Hong Kong 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Ireland Limited ii Ireland 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Overseas Limited England & Wales 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Thailand Limited Thailand 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare UK IP Limited England & Wales 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare UK Trading Limited England & Wales 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare US IP LLC United States 63.5 LLC Interests 100 GlaxoSmithKline Consumer Healthcare A S Denmark 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare AB Sweden 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare AG Switzerland 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Argentina S. A. iv Argentina 63.5 Nominative non endorseable Ordinary 100 GlaxoSmithKline Consumer Healthcare Australia Pty ltd Australia 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare B. V. Netherlands 63.5 Ordinary A 100 GlaxoSmithKline Consumer Healthcare Canada Corp Canada 63.5 Common 100 GlaxoSmithKline Consumer Healthcare Colombia SAS Colombia 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Czech Republic s. r. o. Czech Republic 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Finance Limited England & Wales 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Finland Oy Finland 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare GmbH Austria 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare GmbH & Co. KG Germany 63.5 Partnership Capital 100 GSK Annual Report 2015 255 Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures continued Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Subsidiaries where the effective interest is less than 100% continued GlaxoSmithKline Consumer Healthcare Greece Societe Greece 63.5 Ordinary 100 Anonyme GlaxoSmithKline Consumer Healthcare Holdings US LLC United States 63.5 LLC Interests 100 GlaxoSmithKline Consumer Healthcare Holdings Limited England & Wales 63.5 Ordinary A 100 Ordinary B 0 GlaxoSmithKline Consumer Healthcare Inc. Canada 63.5 Common 100 Preferred 100 GlaxoSmithKline Consumer Healthcare Investments Ireland 63.5 Ordinary 100 Ireland No 2 ii v GlaxoSmithKline Consumer Healthcare Investments Ireland 63.5 Ordinary 100 Ireland No 3 Limited ii v GlaxoSmithKline Consumer Healthcare Japan K. K. Japan 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Korea Co. Ltd. Korea 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare L. L. C. United States 63.5 LLC Interests 100 GlaxoSmithKline Consumer Healthcare Limited India 72.5 Equity 72.5 GlaxoSmithKline Consumer Healthcare Mexico, S. fide R. L. fide C. V. Mexico 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare New Zealand Limited New Zealand 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Norway AS Norway 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Philippines Inc Philippines 63.5 Common 100 GlaxoSmithKline Consumer Healthcare Pte.
Ltd. Singapore 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare S. A. Belgium 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare S. A. Spain 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare S. p. A. Italy 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Sdn.
Malaysia 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Slovakia s. r. o. Slovakia 63.5 Ownership Interest 100 GlaxoSmithKline Consumer Healthcare South Africa Pty Ltd South Africa 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare Sp.
z. o. o. Poland63.5Common 100 GlaxoSmithKline Consumer Healthcare SRL Romania 63.5 Ordinary 100 GlaxoSmithKline Consumer Healthcare, L. P. United States 55.9 Partnership Interest 55.9 GlaxoSmithKline Consumer Healthcare, Produtos para Portugal 63.5 Ordinary Quota 100 a Saude e Higiene, Lda GlaxoSmithKline Consumer Nigeria plc iii Nigeria 46.4 Ordinary 46.4 GlaxoSmithKline Consumer Private Limited India 63.5 Equity 100 GlaxoSmithKline Consumer Trading Services Limited England & Wales 63.5 Ordinary 100 GlaxoSmithKline Costa Rica S. A. Costa Rica 63.5 Ordinary 100 GlaxoSmithKline Dungarvan Limited ii Ireland 63.5 Ordinary 100 GlaxoSmithKline Healthcare AO Russia 63.5 Ordinary 100 GlaxoSmithKline Healthcare GmbH Germany 63.5 Ordinary 100 GlaxoSmithKline Healthcare Ukraine O. O. O. Ukraine 63.5 Ownership Interest 100 GlaxoSmithKline Landholding Company, Inc Philippines 39.9 Common 100 GlaxoSmithKline Limited Kenya 63.5 Ordinary 100 GlaxoSmithKline OTC PVT.
Limited Pakistan 63.5 Ordinary 100 GlaxoSmithKline Pakistan Limited Pakistan 82.6 Ordinary 82.6 GlaxoSmithKline Panama S. A. Panama 63.5 Ordinary 100 GlaxoSmithKline Paraguay S. A. Paraguay 63.5 Ordinary 100 GlaxoSmithKline Pharmaceuticals Limited India 75 Equity 75 GlaxoSmithKline S. A. E. Egypt 91.2 Ordinary 91.2 GlaxoSmithKline Sante Grand Public SAS France 63.5 Ordinary 100 GlaxoSmithKline Tuketici Sagligi Anonim Sirketi Turkey 63.5 Nominative 100  Hungary Limited Liability Company Hungary 63.5 Membership 100 GSK Consumer Healthcare Singapore Pte.
Ltd Singapore 63.5 Ordinary 100 Iodosan S. p. A. Italy 63.5 Ordinary 100 Kuhs GmbH Germany 63.5 Equity 100 Laboratorios ViiV Healthcare, S. L. Spain 78.3 Ordinary 100 Modern Pharma Trading Company L. L. C. Egypt 98.2 Quotas 98.2 Novartis Consumer Health Australasia Pty Ltd Australia 63.5 Ordinary 100 Redeemable Preference 100 Novartis Consumer Health Canada Inc. Novartis Sante Canada 63.5 Common 100 Familiale Canada, Inc. Novartis Consumer Health GmbH Germany 38.1 Ordinary 100 Novartis Consumer Health LLC Russia 63.5 Participation Interest 100 256 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Subsidiaries where the effective interest is less than 100% continued Novartis Consumer Health N. V. Belgium 63.5 Ordinary 100 Novartis Consumer Health S. A. Spain 63.5 Ordinary 100 Novartis Consumer Health S. A. Switzerland 63.5 Ordinary 100 Novartis Consumer Health Schweiz AG Switzerland 63.5 Ordinary 100 Novartis Consumer Health Services S. A. Switzerland 63.5 Registered Shares 100 Novartis Consumer Health UK Limited England & Wales 63.5 Ordinary 100 Novartis Consumer Health, Inc. United States 63.5 Common 100 Novartis Consumer Health-Gebro GmbH Austria 38.1 Ordinary 60 Novartis Sante Familiale S. A. S. In liquidation France 63.5 Ordinary 100 P. T. SmithKline Beecham Pharmaceuticals Indonesia 99 A Shares 100 B Shares 100 P. T. Sterling Products Indonesia Indonesia 63.5 A Shares 100 B Shares 100 Panadol GmbH Germany 63.5 Ordinary 100 PHIVCO Jersey II Limited iv v Jersey 78.3 Ordinary 100 PHIVCO Jersey Limited iv v Jersey 78.3 Ordinary 100 PHIVCO UK II Limited England & Wales 78.3 Ordinary 100 PHIVCO UK Limited England & Wales 78.3 Ordinary 100 PHIVCO-1 LLC United States 78.3 LLC Interests 100 PHIVCO-2 LLC United States 78.3 LLC Interests 100 PT Glaxo Wellcome Indonesia Indonesia 95 A Shares 100 B Shares 100 PT.
Bina Dentalindo In liquidation Indonesia 63.5 Ordinary 100 Shionogi-ViiV Healthcare LLC iv United States 78.3 Common Interests 100 Sino-American Tianjin Smith Kline & French Laboratories Ltd China 34.9 Ordinary 55 SmithKline Beecham Private Limited Sri Lanka 99.6 Ordinary 99.6 SmithKline Beecham Research Limited England & Wales 63.5 Ordinary 100 SmithKline Beecham S. A. Spain 63.5 Ordinary 100 SmithKline Beecham-Biomed O. O. O. Russia 97 Participation Interest 97 Stafford-Miller Ireland Limited ii Ireland 63.5 Ordinary 100 Stafford-Miller Limited England & Wales 63.5 Ordinary 100 Non-Cumulative Non Redeemable Preference 100 Sterling Drug Malaya Sdn Berhad Malaysia 63.5 Ordinary 100 Sterling Products International, Incorporated iv United States 63.5 Common 100 Stiefel Consumer Healthcare UK Limited England & Wales 63.5 Ordinary 100 Stiefel Egypt LLC iv Egypt 99 Quota 99 Stiefel Manufacturing Ireland Limited ii Ireland 63.5 Ordinary 100 ViiV Healthcare South Africa Proprietary Limited South Africa 78.3 Ordinary 100 ViiV Healthcare BV Netherlands 78.3 Ordinary 100 ViiV Healthcare Company United States 78.3 Common 100 ViiV Healthcare Finance 1 Limited iv England & Wales 78.3 Ordinary 100 ViiV Healthcare Finance 2 Limited iv England & Wales 78.3 Ordinary 100 ViiV Healthcare GmbH Germany 78.3 Ordinary 100 ViiV Healthcare GmbH Switzerland 78.3 Ordinary 100 ViiV Healthcare Kabushiki Kaisha Japan 78.3 Ordinary 100 ViiV Healthcare Limited England & Wales 78.3 Class A Shares 100 Class B Shares 0 Class C Shares 0 Class D1 Preference 0 Class D2 Ordinary 0 ViiV Healthcare Overseas Limited England & Wales 78.3 Ordinary 100 ViiV Healthcare Pty Ltd Australia 78.3 Ordinary 100 ViiV Healthcare Puerto Rico, LLC Puerto Rico 78.3 LLC Interests 100 ViiV Healthcare S. r. l. Italy 78.3 Quota 100 ViiV Healthcare SAS France 78.3 Ordinary 100 ViiV Healthcare sprl Belgium 78.3 Ordinary 100 ViiV Healthcare Trading LLC Russia 78.3 Participation Interest 100 ViiV Healthcare Trading Services UK Limited England & Wales 78.3 Ordinary 100 ViiV Healthcare UK No.
2 Limited v Jersey 78.3 Ordinary 100 ViiV Healthcare UK No.
3 Limited England & Wales 78.3 Ordinary 100 ViiV Healthcare UK No.
4 Limited iv England & Wales 78.3 Ordinary 100 ViiV Healthcare UK Limited England & Wales 78.3 Ordinary 100 GSK Annual Report 2015 257 Strategic report Governance & remuneration Financial statements Investor information Other statutory disclosures continued Group companies continued Country of Effective % % Held by Name incorporation Ownership Security Class of Share Subsidiaries where the effective interest is less than 100% continued ViiV Healthcare ULC Canada 78.3 Common 100 ViiV Healthcare Venture LLC United States 78.3 LLC Interests 100 ViiV HIV Healthcare Unipessoal Lda Portugal 78.3 Quota 100 Winster Pharmaceuticals Limited Nigeria 46.4 Ordinary 100 Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd China 95 Ordinary 95 Associates Calci Medica Inc. United States 33.9 Series A and Junior Preferred 33.9 Index Ventures Life VI Jersey LP United States 25 Partnership Interest 25 Theravance, Inc. now Innoviva, Inc. United States 27.8 Common 27.8 JCR Pharmaceuticals Co. Ltd Japan 24.6 Common 24.6 Kurma Biofund II, FCPR France 32 Partnership Interest 32 Longwood Founders Fund LP United States 28 Partnership Interest 28 River Vision Development Corp. United States 33 Series A Preferred 33 Joint Ventures Chiron Panacea Vaccines Private Ltd In liquidation India 50 Japan Vaccine Co. Ltd Japan 50 Japan Vaccine Distribution Co. Ltd Japan 50 Qualivax Pte Limited Singapore 50 Qura Therapeutics LLC United States 50 Key i Directly owned by GlaxoSmithKline plc.
ii Exempt from the provisions of section 347 and 348 of the Companies Act 2014 Ireland, in accordance with the exemptions noted in Section 357 of that Act.
iii C onsolidated as a subsidiary in accordance with section 1162 4 a of the Companies Act 2006 on the grounds of dominant inuence.
vi Entity expected to be disposed of or removed in 2016.
258 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Glossary of terms Terms used in the Annual Report US equivalent or brief description Accelerated capital allowances T ax allowance in excess of depreciation arising from the purchase of xed assets that delay the charging and payment of tax.
The equivalent of tax depreciation.
American Depositary Receipt ADR Receipt evidencing title to an AD S. Each GSK ADR represents two Ordinary Shares.
American Depositary Shares ADS Listed on the New York Stock Exchange: represents two Ordinary Shares.
Basic earnings per share Basic income per share.
Called up share capital Ordinary Shares, issued and fully paid.
CER growth Growth at constant exchange rates.
Corporate Integrity Agreement CIA In 20 12, the company entered into a settlement with the US Federal Government related to past sales and marketing practices.
As part of the settlement the company entered into a Corporate Integrity Agreement with the US Department of Health and Human Services, under which improvements are being built into its existing compliance programmes.
Currency swap An exc hange of two currencies, coupled with a subsequent re-exchange of those currencies, at agreed exchange rates and dates.
Dened benefit plan Pension plan with specic employee benets, often called final salary scheme.
Dened contribution plan P ension plan with specic contributions and a level of pension dependent upon the growth of the pension fund.
Derivative financial instrument A financial instrument that derives its value from the price or rate of some underlying item.
Diluted earnings per share Diluted income per share.
Employee Share Ownership Plan Trusts Trusts established by the Group to satisfy share-based employee incentive plans.
Equity Shareholders funds Shareholders equity.
Freehold Ownership with absolute rights in perpetuity.
The Group GlaxoSmithKline plc and its subsidiary undertakings.
GSK GlaxoSmithKline plc and its subsidiary undertakings.
Hedging The reduction of risk, normally in relation to foreign currency or interest rate movements, by making off-setting commitments.
Intangible xed assets Assets without physical subst ance, such as computer software, brands, licences, patents, know-how and marketing rights purchased from outside parties.
Novartis transaction The three-part inter-conditional transaction with Novartis AG involving the Consumer Healthcare, Vaccines and Oncology businesses completed on 2 March 2015.
Ordinary Share A fully paid up ordinary share in the capital of the company.
profit attributable to shareholders Net income.
Share capital Ordinary Shares, capital stock or common stock issued and fully paid.
Share premium account Additional paid-up capital or paid-in surplus not distributable.
Shares in issue The number of shares outstanding.
Subsidiary An entity in which GSK exercises control.
UK Corporate Governance Code As required by the UK Listing Authority, the company has disclosed in the Annual Report how it has applied the best practice corporate governance provisions of the Financial Reporting Councils UK Corporate Governance Code.
GSK Annual Report 2015 259 Strategic report Governance & remuneration Financial statements Investor information Index Page Page Accountability 85 Long-term Incentive awards 109 Accounting principles and policies 142 Major restructuring costs 156 Acquisitions and disposals 185 Movements in equity 181 Adjustments reconciling profit after tax to operating Net debt 178 cash ows 183 New accounting requirements 148 Annual General Meeting 2016 243 Non-controlling interests 189 Assets held for sale 168 Non-controlling interests in ViiV Healthcare 70 Associates and joint ventures 157 Non-Executive Directors fees 118 Board governance 80 Notes to the financial statements 142 Cash and cash equivalents 168 Operating profit 154 CEOs statement 7 Other intangible assets 164 Chairmans statement 6 Other investments 167 Commitments 191 Other non-current assets 167 Committee reports 88 Other non-current liabilities 178 Competition 10 Other operating income 153 Consolidated balance sheet 139 Other provisions 177 Consolidated cash ow statement 141 Our approach to risk 16 Consolidated income statement 138 Our behaviour 44 Consolidated statement of changes in equity 140 Our Board 74 Consolidated statement of comprehensive income 138 Our business 4 Consumer Healthcare 32 Our global marketplace 8 Consumer Healthcare products and competition 230 Our people 46 Contingent liabilities 179 Our planet 48 Corporate Executive Team 78 Our strategy priorities 12 Corporate governance 80 Overview of 2015 total pay 115 Critical accounting policies 70 Pensions and other post-employment benets 169 Directors and senior management 126Pharmaceuticals 18 Directors interests in shares 119 Pharmaceutical products, competition and Directors statement of responsibilities 130 intellectual property 228 Dividends 160Pipeline 225 Donations to political organisations and Post balance sheet events 204 political expenditure 249 Presentation of the financial statements 142 Earnings per share 160 Principal Group companies 205 Employee costs 155 Property, plant and equipment 161 Employee share schemes 202 Quarterly trend 218 Exchange rates 148 Reconciliation of net cash ow to movement in net debt 184 Executive Director remuneration 103Registrar 246 Finance expense 157 Related party transactions 183 Finance income 156 Relations with shareholders 87 Financial instruments and related disclosures 192 Remuneration governance 116 Financial position and resources 66 Remuneration policy summary 127 Financial statements of GlaxoSmithKline plc, prepared Remuneration report 102 under UK GAAP 211 Research and development 4 Five year record 222 Responsible business 38 Glossary of terms 259 Risk factors 231 Goodwill 162 Segment information 149 Group companies 250 Share capital and control 241 Group financial review 50 Share capital and share premium account 180 Health for all 41 Share price 241 Independent Auditors report 131 Shareholder information 241 Inventories 168Taxation 158 Investments in associates and joint ventures 166 Tax information for shareholders 244 Investor relations 247 Trade and other payables 169 Key accounting judgements and estimates 146 Trade and other receivables 168 Key performance indicators 14 US law and regulation 248 Leadership and effectiveness 83Vaccines 26 Legal proceedings 206 Viability statement 52 260 GSK Annual Report 2015
